<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439320</url>
  </required_header>
  <id_info>
    <org_study_id>16888</org_study_id>
    <secondary_id>H8H-CD-LAHJ</secondary_id>
    <secondary_id>COL MIG-301</secondary_id>
    <nct_id>NCT02439320</nct_id>
  </id_info>
  <brief_title>Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:</brief_title>
  <acronym>SAMURAI</acronym>
  <official_title>A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CoLucid Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized, double-blind, placebo-controlled study in participants with
      disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be asked to treat a migraine attack with study drug on an outpatient basis.
      Participants will be provided with a dosing card containing a dose for initial treatment and
      a second dose to be used for rescue or recurrence of migraine. Each participant's study
      participation will consist of a screening visit (Visit 1) with a telephone contact within 7
      days to confirm eligibility, a Treatment Period of up to 8 weeks, and an End-of-Study (EoS)
      visit (Visit 2) within one week (7 days) of treating a single migraine attack. The total time
      on study is approximately 11 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Headache Pain Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Have Headache Relief After First Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Headache Recurrence</measure>
    <time_frame>From 2 hours post dose up to 48 hours</time_frame>
    <description>Participants who received study drug and which became pain free at 2 hours post-dose and worsened again up to 48 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Used Rescue Medication</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Used Rescue Medication</measure>
    <time_frame>Anytime between 2-24 hours post dose</time_frame>
    <description>Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Used Rescue Medication</measure>
    <time_frame>Anytime 24-48 hours post dose</time_frame>
    <description>Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Nausea Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants without nausea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Phonophobia Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants without phonophobia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Photophobia Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants without photophobia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Serious Adverse Events (SAE)</measure>
    <time_frame>Baseline up to 11 weeks</time_frame>
    <description>Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Resource Utilization</measure>
    <time_frame>6 months prior to enrolling in study to end of study (Up to 11 Weeks) within 7 days of treating a single migraine attack</time_frame>
    <description>Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2231</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Lasmiditan 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet. Lasmiditan 100 mg plus placebo (to match 200 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet. Lasmiditan 200 mg plus placebo (to match 100 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral tablet. Placebo tablets match lasmiditan 100 mg and lasmiditan 200 mg. One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan 100 mg</intervention_name>
    <arm_group_label>Lasmiditan 100 mg</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan 200 mg</intervention_name>
    <arm_group_label>Lasmiditan 200 mg</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (matches lasmiditan doses)</intervention_name>
    <arm_group_label>Lasmiditan 100 mg</arm_group_label>
    <arm_group_label>Lasmiditan 200 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to give written informed consent.

          -  Participants with migraine with or without aura fulfilling the International Headache
             Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Headache Classification
             (ICHD) 2004).

          -  History of disabling migraine for at least 1 year.

          -  MIDAS score ≥11.

          -  Migraine onset before the age of 50 years.

          -  History of 3 - 8 migraine attacks per month (&lt; 15 headache days per month).

          -  Male or female, aged 18 years or above.

          -  Females of child-bearing potential must be using or willing to use a highly effective
             form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD),
             abstinence or vasectomized partner).

          -  Able and willing to complete an electronic diary.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women.

          -  Women of child-bearing potential not using or not willing to use highly effective
             contraception.

          -  Known coronary artery disease, clinically significant arrhythmia or uncontrolled
             hypertension.

          -  History or evidence of hemorrhagic stroke, epilepsy or any other condition placing the
             participant at increased risk of seizures.

          -  History of recurrent dizziness and/or vertigo including benign paroxysmal positional
             vertigo (BPPV), Meniere's disease, vestibular migraine, and other vestibular
             disorders.

          -  History of diabetes mellitus with complications (diabetic retinopathy, nephropathy or
             neuropathy).

          -  History within the previous three years or current evidence of abuse of any drug,
             prescription or illicit, or alcohol.

          -  History of orthostatic hypotension with syncope.

          -  Significant renal or hepatic impairment.

          -  Participant is at imminent risk of suicide (positive response to question 4 or 5 on
             the C-SSRS) or had a suicide attempt within six months prior to the screening visit.

          -  Known Hepatitis B or C or HIV infection.

          -  History, within past 12 months, of chronic migraine or other forms of primary or
             secondary chronic headache disorder (e.g. hemicranias continua, medication overuse
             headache) where headache frequency is greater than 15 headache days per month.

          -  Use of more than 3 doses per month of either opiates or barbiturates.

          -  Initiation of or a change in concomitant medication to reduce the frequency of
             migraine episodes within three (3) months prior to Screening/Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southview Medical Group, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simon-Williamson Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Valley Family Physicians, PC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research,Inc</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Family Practice</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage/Fountain Hills Family Practice</name>
      <address>
        <city>Fountain Hills</city>
        <state>Arizona</state>
        <zip>85268</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Physicians of Arizona, Inc</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunderbird Internal Medicine</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenzmeier Family Practice</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Arizona Medical Associates, PC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Clinical Research</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Practice Specialists, Ltd</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage Inc./Central Phoenix Medical Center LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunderbird Internal Medicine</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tatum Highlands Medical Associates, PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiel Family and Sports Medicine</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Community Physicians</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Grove Family Practice</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cassidy Medical Group</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Clinical Research</name>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cassidy Medical Group</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mile High Primary Care</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage Inc/Colorado Springs Family Practice</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Development- Washington DC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urban Family Practice</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Neurology and Sleep Medicine Associates</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Avenue Internists</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical and Procedural Specialists of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Premier Research LLC</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medical Associates</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ridge Family Practice</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc./Continuum Health Care</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Florissant Internists</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyline Medical Center</name>
      <address>
        <city>Elkhorn</city>
        <state>Nebraska</state>
        <zip>68022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Fields Family Medicine PC</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Family Physicians, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Mell, DO</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Family Care</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Center of Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Center of Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clifford Molin/Clinical Research Advantage,Inc</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Development - Queens NY</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research,Inc</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma City Clinic - Edmund</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma City Clinic - Midwest CIty</name>
      <address>
        <city>Midwest City</city>
        <state>Oklahoma</state>
        <zip>73110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LION Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma City Clinic- Central/Clinical Research Advantage INC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunstone Medical Research,LLC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Bay Clinical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Care Associates, PA</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medical Associates of Texas</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <zip>75013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Family Physicians</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Village Health Center</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors of Internal Medicine</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plano Internal Medicine</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <results_first_submitted>November 8, 2019</results_first_submitted>
  <results_first_submitted_qc>November 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2019</results_first_posted>
  <disposition_first_submitted>April 3, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 3, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 5, 2018</disposition_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomized in a double-blind, placebo-controlled parallel group study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>100 mg Lasmiditan</title>
          <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
        </group>
        <group group_id="P2">
          <title>200 mg Lasmiditan</title>
          <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="744"/>
                <participants group_id="P2" count="745"/>
                <participants group_id="P3" count="742"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Confirmed Eligibility</title>
              <participants_list>
                <participants group_id="P1" count="710"/>
                <participants group_id="P2" count="695"/>
                <participants group_id="P3" count="705"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1st Dose (by 4 Hours Migraine Onset)</title>
              <participants_list>
                <participants group_id="P1" count="630"/>
                <participants group_id="P2" count="609"/>
                <participants group_id="P3" count="617"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2nd Dose (After 2 Hour Assessment)</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="238"/>
                <participants group_id="P3" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="648"/>
                <participants group_id="P2" count="631"/>
                <participants group_id="P3" count="643"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with Protocol</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization Failure</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>100 mg Lasmiditan</title>
          <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose</description>
        </group>
        <group group_id="B2">
          <title>200 mg Lasmiditan</title>
          <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="630"/>
            <count group_id="B2" value="609"/>
            <count group_id="B3" value="617"/>
            <count group_id="B4" value="1856"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="11.67"/>
                    <measurement group_id="B2" value="41.4" spread="12.04"/>
                    <measurement group_id="B3" value="42.4" spread="12.30"/>
                    <measurement group_id="B4" value="42.0" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="512"/>
                    <measurement group_id="B2" value="515"/>
                    <measurement group_id="B3" value="525"/>
                    <measurement group_id="B4" value="1552"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="544"/>
                    <measurement group_id="B2" value="527"/>
                    <measurement group_id="B3" value="529"/>
                    <measurement group_id="B4" value="1600"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Unknown or Not reported row is listed as Other in the Clinical Study Report.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="366"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="471"/>
                    <measurement group_id="B2" value="450"/>
                    <measurement group_id="B3" value="479"/>
                    <measurement group_id="B4" value="1400"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="630"/>
                    <measurement group_id="B2" value="609"/>
                    <measurement group_id="B3" value="617"/>
                    <measurement group_id="B4" value="1856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Migraine History</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.7" spread="12.98"/>
                    <measurement group_id="B2" value="18.9" spread="13.12"/>
                    <measurement group_id="B3" value="19.3" spread="12.65"/>
                    <measurement group_id="B4" value="19.3" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Are Headache Pain Free</title>
        <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable headache pain free data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Headache Pain Free</title>
          <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable headache pain free data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="518"/>
                <count group_id="O3" value="524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="32.2"/>
                    <measurement group_id="O3" value="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free</title>
        <description>The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable MBS data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free</title>
          <description>The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable MBS data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="469"/>
                <count group_id="O2" value="481"/>
                <count group_id="O3" value="488"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="40.7"/>
                    <measurement group_id="O3" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Have Headache Relief After First Dose</title>
        <description>The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable headache relief data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Headache Relief After First Dose</title>
          <description>The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable headache relief data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="555"/>
                <count group_id="O3" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="59.5"/>
                    <measurement group_id="O3" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Headache Recurrence</title>
        <description>Participants who received study drug and which became pain free at 2 hours post-dose and worsened again up to 48 hours post-dose.</description>
        <time_frame>From 2 hours post dose up to 48 hours</time_frame>
        <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Headache Recurrence</title>
          <description>Participants who received study drug and which became pain free at 2 hours post-dose and worsened again up to 48 hours post-dose.</description>
          <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="555"/>
                <count group_id="O3" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.029</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.002</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Used Rescue Medication</title>
        <description>Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free).</description>
        <time_frame>2 hours post dose</time_frame>
        <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Used Rescue Medication</title>
          <description>Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free).</description>
          <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="555"/>
                <count group_id="O3" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="20.7"/>
                    <measurement group_id="O3" value="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Used Rescue Medication</title>
        <description>Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free).</description>
        <time_frame>Anytime between 2-24 hours post dose</time_frame>
        <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Used Rescue Medication</title>
          <description>Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free).</description>
          <population>Randomized participants who received a dose of study drug and had postdose headache severity or symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="555"/>
                <count group_id="O3" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="7.9"/>
                    <measurement group_id="O3" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.120</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Used Rescue Medication</title>
        <description>Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free).</description>
        <time_frame>Anytime 24-48 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Used Rescue Medication</title>
          <description>Rescue medication was permitted after completion of the 2 hour assessment if the migraine did not respond (participant was not pain free).</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable use of rescue medication data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="555"/>
                <count group_id="O3" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Nausea Free</title>
        <description>The percentage of participants without nausea.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug and had any post-dose headache severity or symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Nausea Free</title>
          <description>The percentage of participants without nausea.</description>
          <population>All randomized participants who used at least 1 dose of study drug and had any post-dose headache severity or symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="555"/>
                <count group_id="O3" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6"/>
                    <measurement group_id="O2" value="64.1"/>
                    <measurement group_id="O3" value="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.386</p_value>
            <method>Regression, Linear</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.470</p_value>
            <method>Regression, Linear</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Phonophobia Free</title>
        <description>The percentage of participants without phonophobia.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug and had any post-dose headache severity or symptom assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Phonophobia Free</title>
          <description>The percentage of participants without phonophobia.</description>
          <population>All randomized participants who used at least 1 dose of study drug and had any post-dose headache severity or symptom assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="555"/>
                <count group_id="O3" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="58.7"/>
                    <measurement group_id="O3" value="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Photophobia Free</title>
        <description>The percentage of participants without photophobia.</description>
        <time_frame>2 hours post dose</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had evaluable photophobia free data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Photophobia Free</title>
          <description>The percentage of participants without photophobia.</description>
          <population>All randomized participants who received at least one dose of study drug and had evaluable photophobia free data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="555"/>
                <count group_id="O3" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9"/>
                    <measurement group_id="O2" value="51.5"/>
                    <measurement group_id="O3" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>02.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Serious Adverse Events (SAE)</title>
        <description>Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section</description>
        <time_frame>Baseline up to 11 weeks</time_frame>
        <population>All randomized participants who had received at least one dose of study drug. Results are displayed by the first dose taken.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO within 4 hours of onset of migraine attack. If the migraine did not respond 2 hours postdose a second dose of study drug can be taken up to 24 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Serious Adverse Events (SAE)</title>
          <description>Safety and Tolerability was assessed by the number of participants with at least 1 treatment emergent event (TEAE). A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section</description>
          <population>All randomized participants who had received at least one dose of study drug. Results are displayed by the first dose taken.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
                <count group_id="O2" value="609"/>
                <count group_id="O3" value="617"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Resource Utilization</title>
        <description>Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study</description>
        <time_frame>6 months prior to enrolling in study to end of study (Up to 11 Weeks) within 7 days of treating a single migraine attack</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug, regardless of whether or not they underwent any study assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan/100 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. An optional 100 mg Lasmiditan dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O2">
            <title>100 mg Lasmiditan/Placebo</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O3">
            <title>200 mg Lasmiditan/200 mg Lasmiditan</title>
            <description>100 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. An optional 100 mg lasmiditan dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O4">
            <title>200 mg Lasmiditan/Placebo</title>
            <description>200 milligrams (mg) lasmiditan administered PO within 4 hours of onset of migraine attack. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Placebo</title>
            <description>Placebo tablets match each of the lasmiditan doses (100 mg and 200 mg) was administered orally, once for acute treatment of migraine. A second optional dose was administered between 2 and 24 hours for rescue or recurrence of migraine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Resource Utilization</title>
          <description>Use of health care for treatment 6 months prior to enrolling in the study and information reported during time on study</description>
          <population>All randomized participants who used at least 1 dose of study drug, regardless of whether or not they underwent any study assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="203"/>
                <count group_id="O5" value="617"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months prior to enrolling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="3.0"/>
                    <measurement group_id="O4" value="2.5"/>
                    <measurement group_id="O5" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During time of study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 11 weeks</time_frame>
      <desc>All randomized participants who had received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>100 mg Lasmiditan</title>
          <description>Any participant who received 100 milligrams (mg) lasmiditan administered PO.</description>
        </group>
        <group group_id="E2">
          <title>200 mg Lasmiditan</title>
          <description>Any participant who received 200 milligrams (mg) lasmiditan administered PO.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Any participant who received placebo administered PO.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="630"/>
                <counts group_id="E2" subjects_affected="280" subjects_at_risk="609"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="630"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="609"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="630"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="609"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="630"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="630"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="609"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="630"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Feeling drunk</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Feeling of relaxation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="609"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="630"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Aura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="630"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Clumsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="91" subjects_affected="87" subjects_at_risk="630"/>
                <counts group_id="E2" events="114" subjects_affected="107" subjects_at_risk="609"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Fine motor skill dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="609"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="630"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="630"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="609"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="42" subjects_at_risk="630"/>
                <counts group_id="E2" events="51" subjects_affected="50" subjects_at_risk="609"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="630"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Sensory integrative dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="630"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="609"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="630"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Tunnel vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Blunted affect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Depersonalisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hypnagogic hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Panic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Phonophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Skin sensitisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="609"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="630"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="609"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="630"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="609"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="617"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="630"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="609"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="617"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>Clinicaltrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

